Matthew Myers will present his Pre FPO "Inferring tumor heterogeneity from DNA sequencing data" on Thursday, January 27, 2022 at 3pm via Zoom
Matthew Myers will present his Pre FPO "Inferring tumor heterogeneity from DNA sequencing data" on Thursday, January 27, 2022 at 3pm via Zoom. Zoom link: https://princeton.zoom.us/j/94807976020?pwd=d21JY2VLZElXbjlCZXJnbjRwL0svUT09 Committee members: Ben Raphael (adviser), Mona Singh, and Olga Troyanskaya; Readers: Yuri Pritykin and Quaid Morris (Sloan Kettering Institute) All are welcome to attend. Title: Inferring tumor heterogeneity from DNA sequencing data Abstract: Cancer is an evolutionary process where cells acquire somatic mutations over time at various genomic scales, from single-position changes (single-nucleotide variations or SNVs), to changes in the number of copies (copy number aberrations or CNAs) of larger regions of the genome, to duplication of the entire genome (whole-genome duplication or WGD). As a result of this process, each tumor is heterogeneous -- it consists of a mixture of different populations of cells, or clones, each characterized by a distinct set of mutations. Understanding these clones and their evolution is critical to treating many cancers. In this talk, I will present three computational methods for inferring tumor heterogeneity from DNA sequencing data. First, I will present CALDER, which uses SNVs from longitudinal bulk sequencing samples to infer a phylogenetic tree which defines the tumor clones and their evolutionary relationships. Unlike prior methods, CALDER applies constraints derived from the sequential ordering of samples to produce more plausible trees. Next, I will present HATCHet2, which infers CNAs from one or more bulk DNA sequencing samples. HATCHet2 combines several innovations including reference-based phasing and location-aware clustering with the novel factorization approach of HATCHet. Finally, I will present SBMClone, which uses SNVs identified from ultra-low-coverage single-cell DNA sequencing data to group tumor cells. SBMClone uses a stochastic block model to distinguish tumor cells in data that was too sparse for previous methods.
participants (1)
-
Nicki Mahler